bullish
Takeda Pharma Divests Yet Another Non-Core Asset to Pay-Off Debt and Focus on Core Areas
394 Views29 Apr 2020 14:02
On 24th April, Takeda Pharmaceutical announced that it has entered into an agreement to sell off a portfolio of select non-core over the counter...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Hygeia Healthcare IPO (Part I): A Better Healthcare16 Jun 2020
- Fujifilm Invests US$928m to Expand Its Bio-CDMO Capacity16 Jun 2020
- Takeda Offloads Asia-Focused Drugs to South Korea’s Celltrion12 Jun 2020
- Palo Alto Buys Cloud Services Firm CloudGenix to Make Up for Declining Legacy Hardware Business07 Apr 2020
- J&J’s Purchase of Takeda’s Surgical Patch Subject to EU Investigation; Expect a Deal Anyways02 Apr 2020
- Japan’s Astellas Pharma Buys US-Based Xyphos Biosciences Inc.30 Dec 2019
x